Evaxion Biotech A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
1.640
+0.050 (3.14%)
At close: Apr 25, 2025, 4:00 PM
1.660
+0.020 (1.22%)
After-hours: Apr 25, 2025, 4:24 PM EDT

Evaxion Biotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Revenue
3.340.07---
Upgrade
Revenue Growth (YoY)
4480.82%----
Upgrade
Gross Profit
3.340.07---
Upgrade
Selling, General & Admin
7.6210.358.216.255.67
Upgrade
Research & Development
10.4611.9217.0619.5810.9
Upgrade
Operating Expenses
18.0822.2725.2625.8316.57
Upgrade
Operating Income
-14.73-22.2-25.26-25.83-16.57
Upgrade
Interest Expense
-0.96-0.9-0.8-0.16-0.03
Upgrade
Interest & Investment Income
0.250.150.01--
Upgrade
Currency Exchange Gain (Loss)
0.18-0.261.711.280.02
Upgrade
Other Non Operating Income (Expenses)
3.90.280.4--
Upgrade
Pretax Income
-11.36-22.92-23.94-24.71-16.58
Upgrade
Income Tax Expense
-0.79-0.79-0.77-0.18-1.56
Upgrade
Net Income
-10.57-22.13-23.17-24.53-15.02
Upgrade
Net Income to Common
-10.57-22.13-23.17-24.53-15.02
Upgrade
Shares Outstanding (Basic)
11000
Upgrade
Shares Outstanding (Diluted)
11000
Upgrade
Shares Change (YoY)
96.24%15.64%21.27%26.29%11.10%
Upgrade
EPS (Basic)
-9.85-40.47-49.01-62.92-48.65
Upgrade
EPS (Diluted)
-9.85-40.47-49.01-62.92-48.65
Upgrade
Free Cash Flow
-12.94-17.78-26.07-23.23-12.59
Upgrade
Free Cash Flow Per Share
-12.06-32.52-55.13-59.59-40.77
Upgrade
Gross Margin
100.00%100.00%---
Upgrade
Operating Margin
-440.55%-30406.85%---
Upgrade
Profit Margin
-316.00%-30308.22%---
Upgrade
Free Cash Flow Margin
-386.96%-24353.42%---
Upgrade
EBITDA
-14.37-21.83-24.69-25.49-16.46
Upgrade
D&A For EBITDA
0.360.370.570.340.11
Upgrade
EBIT
-14.73-22.2-25.26-25.83-16.57
Upgrade
Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q